Gilead Sciences, Inc. (BIT:1GILD)

Italy flag Italy · Delayed Price · Currency is EUR
94.40
+0.52 (0.55%)
At close: Jul 1, 2025, 5:30 PM CET
47.16%
Market Cap 117.79B
Revenue (ttm) 26.59B
Net Income (ttm) 5.52B
Shares Out n/a
EPS (ttm) 4.38
PE Ratio 21.34
Forward PE 13.54
Dividend 2.87 (3.04%)
Ex-Dividend Date Mar 13, 2025
Volume 582
Average Volume 206
Open 94.00
Previous Close 93.88
Day's Range 93.94 - 94.77
52-Week Range 61.18 - 111.00
Beta 0.31
RSI 51.19
Earnings Date Aug 1, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
Founded 1987
Employees 17,600
Stock Exchange Borsa Italiana
Ticker Symbol 1GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

There is no news available yet.